Does Blue Cross Blue Shield of Michigan Cover Farxiga?

What Is Farxiga and Why Does Coverage Complexity Matter?

Farxiga is a once-daily oral SGLT2 inhibitor whose active molecule, dapagliflozin, blocks glucose reabsorption in the proximal tubule of the kidney. Beyond blood sugar control in type 2 diabetes (T2D), the FDA has approved it for three additional indications since 2020, and each separate approval can affect how an insurer classifies and covers the drug.

The Four FDA-Approved Indications

The FDA first approved dapagliflozin for T2D in January 2014 under NDA 202293 (FDA label). Three subsequent approvals followed:

• Heart failure with reduced ejection fraction (HFrEF): Approved May 2020, based on the DAPA-HF trial.
• Chronic kidney disease (CKD): Approved April 2021, based on the DAPA-CKD trial.
• Heart failure with preserved ejection fraction (HFpEF): Approved May 2022, based on the DELIVER trial.

Each new indication widened the pool of patients who can argue medical necessity when a claim is denied.

Why These Indications Affect Your Insurance Claim

BCBS Michigan plan documents often list Farxiga under the diabetes formulary section. If your prescribing diagnosis code is I50.2 (systolic heart failure) rather than E11.9 (type 2 diabetes without complications), a claim submitted under the wrong benefit category may be automatically denied even when the drug is technically covered. Your prescriber should confirm the ICD-10 code on the prior authorization form matches the approved indication for your condition.

How BCBS Michigan Formularies Work

A formulary is a tiered drug list that determines how much you pay at the pharmacy. Blue Cross Blue Shield of Michigan operates several distinct plan types, and each carries its own formulary.

Commercial Plans (Employer-Sponsored and Individual Marketplace)

Most BCBS Michigan commercial plans place Farxiga on Tier 3 (preferred brand) rather than Tier 2 (generic/preferred generic). The practical effect is a higher copay, typically $50 to $100 for a 30-day supply without any assistance program. Generic dapagliflozin is not yet available in the United States, so there is no lower-cost substitution option as of early 2025.

The American Diabetes Association's 2024 Standards of Care designate SGLT2 inhibitors as preferred add-on agents for patients with T2D who also have established cardiovascular disease, heart failure, or CKD (ADA Standards of Care 2024). That guideline language is directly useful when writing a letter of medical necessity.

Medicare Advantage Plans

BCBS of Michigan offers several Medicare Advantage products, including Blue Cross Complete and various PPO options. On Medicare Advantage formularies, dapagliflozin generally falls on Tier 4 or Tier 5 (specialty tier), which can mean 25 to 33% coinsurance rather than a flat copay. The AstraZeneca savings card does NOT apply to Medicare Advantage patients, but Extra Help (Low Income Subsidy) may reduce costs significantly.

A 2023 analysis in JAMA Internal Medicine found that SGLT2 inhibitor use among Medicare beneficiaries with heart failure remained low partly because of out-of-pocket cost barriers, underscoring that formulary placement has real clinical consequences (PMID 37273215).

Medicaid Managed Care (Blue Cross Complete of Michigan)

Blue Cross Complete of Michigan administers Medicaid managed care in the state. Farxiga appears on the Michigan Medicaid preferred drug list subject to prior authorization. Copays for Medicaid enrollees are nominal (often $1, $4), but the prior authorization hurdle still applies.

Prior Authorization Requirements for Farxiga at BCBS Michigan

Prior authorization (PA) is the most common barrier to filling Farxiga at BCBS Michigan. Understanding exactly what the plan requires speeds up approval.

Typical PA Criteria for the Diabetes Indication

BCBS Michigan commercial PA criteria for Farxiga in T2D generally require all of the following:

1. Confirmed diagnosis of type 2 diabetes (not type 1).
2. HbA1c above a threshold, often 7.5% or higher, documented within the past 12 months.
3. Trial of at least one first-line agent, typically metformin, unless there is a documented contraindication or intolerance.
4. Prescriber is an internist, family physician, or endocrinologist (not always required, but recommended to reduce delays).

The ADA notes that metformin remains a cost-effective first-line agent, and that SGLT2 inhibitors should be added when additional cardiovascular or renal benefit is needed regardless of baseline HbA1c (ADA 2024, Section 9). Citing this guideline in a PA request strengthens the medical necessity argument.

PA Criteria for Heart Failure and CKD Indications

For heart failure indications, PA requests typically require:

• Echocardiogram documenting ejection fraction (EF <40% for HFrEF; EF >40% for HFpEF).
• NYHA functional class II, IV documented in the chart.
• Current standard-of-care background therapy (ACE inhibitor or ARB, beta-blocker, and mineralocorticoid antagonist for HFrEF, per ACC/AHA guidelines).

The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) (NEJM 2019, PMID 31535829). Providing this citation in your PA letter gives the medical reviewer a specific outcome number to consider.

For CKD, DAPA-CKD (N=4,304) demonstrated a 44% relative risk reduction in the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.56, 95% CI 0.45 to 0.70, P<0.001) (NEJM 2020, PMID 32970396). PA requests for CKD should document baseline eGFR (15 to 75 mL/min/1.73 m²) and urine albumin-to-creatinine ratio (UACR >200 mg/g is typical), mirroring the DAPA-CKD enrollment criteria.

Turnaround Times and Urgent Requests

Standard PA decisions at BCBS Michigan must be issued within 14 calendar days under Michigan Department of Insurance and Financial Services rules. Urgent (expedited) requests require a decision within 72 hours when a standard timeline could seriously jeopardize the member's health. If you are being discharged from a hospital with a new heart failure or CKD diagnosis, ask your care team to submit an expedited PA before discharge.

What to Do If BCBS Michigan Denies Your Farxiga Claim

Denial is not the final word. Multiple appeal pathways exist, and success rates are meaningful.

Step 1: Internal Appeal

You have 180 days from the denial notice to file an internal appeal with BCBS Michigan. Attach:

• The treating physician's letter of medical necessity citing specific guideline language and trial data.
• Relevant lab values (HbA1c, eGFR, UACR, or echocardiogram report).
• The specific FDA-approved indication for which the drug is being prescribed.

The 2010 Affordable Care Act requires internal appeals be decided within 30 days for pre-service requests and 60 days for post-service claims (HHS guidance).

Step 2: External Independent Review

If the internal appeal fails, Michigan law grants you the right to an External Independent Review through the Michigan Department of Insurance and Financial Services (DIFS). An independent medical reviewer, not affiliated with BCBS, examines the case. External reviews overturn insurer decisions in a meaningful proportion of cases, particularly when the denied drug has FDA approval for the patient's documented diagnosis.

Step 3: Michigan DIFS Complaint

Filing a formal complaint with DIFS can accelerate resolution. Visit michigan.gov/difs or call 877-999-6442. DIFS tracks complaint outcomes and can intervene if an insurer is applying PA criteria that conflict with state or federal law.

Farxiga Cost Without Coverage or During a Coverage Gap

If coverage is denied or you are in a Medicare Part D coverage gap, several options reduce out-of-pocket spending.

AstraZeneca Savings Card

AstraZeneca's Farxiga savings card allows eligible commercially insured patients to pay as little as $10 per 30-day supply, up to 13 fills per year. The card is not valid for Medicare, Medicaid, or any government-funded program. Eligibility and terms change periodically; confirm current details at AstraZeneca's patient support program or by calling 1-800-AZandME.

Patient Assistance Program

AstraZeneca's AZ&Me Prescription Savings Program provides Farxiga at no cost to uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level). Applications are processed within 2 to 3 weeks.

GoodRx and Cash-Pay Pricing

GoodRx cash pricing for Farxiga 10 mg (30 tablets) ranged from approximately $480 to $540 at Michigan pharmacies as of early 2025. That figure underscores why insurance coverage or manufacturer assistance is clinically important for treatment adherence.

A 2021 study in Circulation found that patients who faced high out-of-pocket costs for evidence-based heart failure medications had measurably higher rates of medication discontinuation, which was associated with increased hospitalization risk (PMID 34370512). Cost-related non-adherence is a documented clinical problem, not an abstract concern.

The Clinical Evidence That Strengthens a BCBS Michigan Coverage Argument

When your physician writes a prior authorization or appeal letter, grounding it in specific trial data matters. Here are the key studies to reference.

DAPA-HF: Heart Failure With Reduced Ejection Fraction

DAPA-HF enrolled 4,744 patients with HFrEF (EF <40%) across 20 countries. Dapagliflozin 10 mg daily reduced the primary composite endpoint (worsening HF or CV death) by 26% vs. Placebo over a median 18.2 months (HR 0.74, P<0.001). The benefit was consistent whether or not patients had T2D (NEJM 2019, PMID 31535829).

The ACC/AHA 2022 Heart Failure Guideline gives SGLT2 inhibitors a Class I, Level of Evidence A recommendation for patients with HFrEF regardless of diabetes status (Circulation 2022, PMID 35363499). Class I, Level A is the highest possible recommendation strength.

DELIVER: Heart Failure With Preserved Ejection Fraction

DELIVER (N=6,263) showed dapagliflozin reduced the primary composite of worsening HF or CV death by 18% vs. Placebo in patients with HFpEF (EF >40%) (HR 0.82, 95% CI 0.73 to 0.92, P<0.001) (NEJM 2022, PMID 35900821). This was the key trial supporting the 2022 FDA approval for HFpEF.

DAPA-CKD: Chronic Kidney Disease

DAPA-CKD (N=4,304) enrolled adults with eGFR 25 to 75 mL/min/1.73 m² and UACR 200 to 5,000 mg/g. Dapagliflozin reduced the composite kidney/CV endpoint by 39% compared to placebo (HR 0.61, P<0.001) (NEJM 2020, PMID 32970396). The trial was stopped early for efficacy.

DECLARE-TIMI 58: Cardiovascular Safety in T2D

DECLARE-TIMI 58 (N=17,160) confirmed that dapagliflozin does not increase major adverse cardiovascular events (MACE) in patients with T2D who have multiple CV risk factors, and it significantly reduced hospitalization for heart failure (HR 0.73, P<0.001) (NEJM 2019, PMID 30415602). This cardiovascular safety data supports medical necessity arguments in T2D patients at elevated cardiac risk.

A Step-by-Step Framework: From Prescription to Filled Bottle at BCBS Michigan

The following sequence applies to most BCBS Michigan commercial plan members who are new to Farxiga.

Step 1: Confirm Your Plan's Formulary Placement

Log in to bcbsm.com, manage to "Prescription Drug Coverage," and search for "dapagliflozin" or "Farxiga." Note the tier, any quantity limits, and whether PA is required. If the online tool is unclear, call the member services number on your insurance card.

Step 2: Have Your Prescriber Submit a PA Before You Attempt to Fill

Attempting to fill without PA in place results in a point-of-sale rejection. Your prescriber's office should submit the PA electronically through CoverMyMeds or directly through BCBS Michigan's provider portal. Supplying lab values and chart notes upfront avoids back-and-forth delays.

Step 3: Apply the AstraZeneca Savings Card Simultaneously

Even if PA is pending, obtain the AstraZeneca savings card now. If your PA is approved and your plan still leaves a high copay, the card can offset the remainder for commercially insured patients.

Step 4: Appeal Any Denial Immediately

Do not wait. The 180-day appeal window starts on the date of the denial notice. Waiting erodes your timeline and may delay treatment for a condition with documented mortality risk.

Step 5: Contact Michigan DIFS if the Appeal Fails

DIFS external review is free to patients and binds the insurer to the outcome. The Michigan DIFS consumer hotline is 877-999-6442.

How Farxiga Fits Into Current Diabetes and Cardiorenal Treatment Guidelines

SGLT2 inhibitors occupy an increasingly central position in treatment algorithms from multiple specialty societies, and that guideline prominence directly affects how insurers should classify them.

ADA 2024 Position

The ADA 2024 Standards of Care recommend SGLT2 inhibitors as preferred additions to metformin for patients with T2D who have established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of HbA1c (ADA 2024, PMID 38078589). The guideline explicitly states these agents should be used "to reduce cardiovascular and kidney risk" rather than purely for glycemic control.

KDIGO 2022 CKD Guidelines

The Kidney Disease Improving Global Outcomes (KDIGO) 2022 guidelines recommend SGLT2 inhibitors for all patients with T2D and CKD with eGFR >20 mL/min/1.73 m² to slow CKD progression (KDIGO 2022, PMID 36272651). This is a Grade 1A recommendation, the highest possible strength.

ACC/AHA Heart Failure Guidelines

The 2022 ACC/AHA/HFSA Heart Failure Guideline gives dapagliflozin a Class I recommendation (benefit far outweighs risk) for HFrEF and a Class IIa recommendation for HFpEF (Circulation 2022, PMID 35363499). Quoting class and level of evidence in a PA letter translates guideline authority directly into coverage language that medical reviewers at insurers are trained to respect.

Special Situations That Affect BCBS Michigan Farxiga Coverage

Transitions of Care After Hospitalization

Patients discharged after a heart failure hospitalization are at the highest risk of readmission in the first 30 days. Starting dapagliflozin in the hospital or at discharge has been evaluated in SOLOIST-WHF and related trials. If you are filling Farxiga for the first time after a hospitalization, request an urgent (expedited) PA at the time of discharge planning. Hospitals with a dedicated transitions-of-care pharmacist can submit the PA before the patient leaves the building.

Type 1 Diabetes

Farxiga does NOT have FDA approval for type 1 diabetes as of early 2025, and BCBS Michigan will not cover it for that indication. Prescribing it off-label for T1D carries meaningful diabetic ketoacidosis risk and is not supported by current major guidelines (FDA safety communication on SGLT2 inhibitors in T1D).

Pregnancy

Farxiga is contraindicated in the second and third trimesters of pregnancy. ACOG guidelines advise against use of SGLT2 inhibitors in pregnant patients (ACOG Practice Bulletin on Pregestational Diabetes, acog.org). Any PA submitted during pregnancy should reflect an alternative agent.

Recurrent Urinary Tract Infections

Patients with a history of recurrent urinary tract infections may face clinical hesitation from prescribers, and occasionally insurers will flag this in utilization review. A 2018 meta-analysis in Diabetes Care found SGLT2 inhibitors increased genital mycotic infections (RR 3.5) but did not significantly increase serious urinary tract infections requiring hospitalization (PMID 29246946). That distinction is worth clarifying in a PA if UTI history is raised as a concern.